Brief: Eagle Pharmaceuticals Reports First Quarter 2022 Results
09/05/2022 12:06
May 9 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS REPORTS FIRST QUARTER 2022 RESULTS
* EAGLE PHARMACEUTICALS INC - Q1 2022 NET INCOME WAS $3.47
PER
BASIC AND $3.41 PER DILUTED SHARE
* EAGLE PHARMACEUTICALS INC - QTRLY ADJUSTED NON-GAAP NET
INCOME
WAS $4.10 PER BASIC AND $4.04 PER DILUTED SHARE
* EAGLE PHARMACEUTICALS INC - Q1 2022 TOTAL REVENUE WAS
$115.9
MILLION, UP FROM $41.2 MILLION IN Q1 2021
* EAGLE PHARMACEUTICALS INC - EXPECTS TO START CLINICAL
TRIAL IN
CAL02 PATIENTS IN Q3 2022 DURING PNEUMONIA SEASON
* EAGLE PHARMACEUTICALS INC - REMAINS ON TRACK TO SUPPORT
SUBMISSION OF NEW DRUG APPLICATION LATER THIS MONTH FOR
LANDIOLOL, A BETA-1 ADRENERGIC BLOCKER
* EAGLE PHARMACEUTICALS INC - FY22 ADJUSTED NON-GAAP
RESEARCH AND
DEVELOPMENT EXPENSE IS EXPECTED TO BE IN THE RANGE OF $46
MILLION TO $50 MILLION
Source text for Eikon: ID:nGNX7Cq9ZW
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq